Une contribution à la lutte mondiale contre le paludisme
Malgré des progrès constants dans la maîtrise de la maladie, le paludisme reste encore l’un des principaux fléaux dans de nombreux pays, notamment en Afrique subsaharienne. Dans sa lutte contre les conséquences sanitaires et économiques qui accablent ses pays partenaires, la DDC met l’accent d’une part sur la prévention et d’autre part sur l’accès aux soins.
En point de mire de la DDC
La Suisse jouit d’une reconnaissance mondiale dans le domaine de la recherche et de la mise en place de mesures innovantes pour prévenir et maîtriser le paludisme. La DDC a donc la chance de pouvoir collaborer avec de nombreux partenaires publics et privés reconnus pour leurs connaissances et leur expertise dans le domaine du paludisme.
La DDC contribue à la lutte antipaludique grâce à des partenariats bilatéraux et multilatéraux. Dans les pays où le paludisme est endémique, elle soutient des projets dont l’objectif est la distribution de moustiquaires, le renforcement des systèmes sanitaires et le soutien aux initiatives des communautés locales. Au niveau international, la DDC fournit des contributions financières à des initiatives mondiales telles que le Fonds mondial de lutte contre le SIDA, la tuberculose et le paludisme, à des institutions académiques reconnues internationalement ainsi qu’à des partenariats public-privé qui mènent des recherches pionnières et développent des moyens de prévention, des traitements et des outils diagnostics.
Sensibilisation et prise de conscience
La DDC est aussi à la tête du Swiss Malaria Group (SMG). Fondé en 2007, celui-ci comprend onze membres issus des secteurs public et privé ainsi que de la société civile. L’objectif du SMG consiste à sensibiliser les décideurs et le public au problème du paludisme et à ses conséquences, tout en encourageant la Suisse à soutenir les organisations actives dans la lutte contre cette maladie. Les membres du groupe s’allient pour réduire le nombre de cas de paludisme dans les pays les plus touchés, grâce à des mesures de contrôle innovantes et au partage des connaissances et des ressources financières.
Contexte
De nombreux pays ont réalisé des progrès considérables dans la maîtrise du paludisme, réduisant non seulement le taux de mortalité infantile mais aussi le nombre d’infections. Ces résultats sont dus à une meilleure coordination des différents acteurs à l’échelle mondiale, à des investissements massifs dans la lutte antipaludique et à la mise à disposition d’outils efficaces pour la prévention, le diagnostic et le traitement. Toutefois, le développement de résistances aux médicaments et aux insecticides est un obstacle majeur à la pérennisation de ces acquis.
Liens
Documents
Malaria Factsheet
[de] (PDF, 2 Pages, 376.3 kB)
Improving access to essential malaria treatments with "SMS" in Tanzania
[en] (PDF, 4 Pages, 196.4 kB, Anglais)
Delivery of child-friendly antimalarial hits the 100 million mark
Medicines for Malaria Venture, press release
[en]
(PDF, 4 Pages, 141.6 kB, Anglais)
Projets actuels
Objet 1 9 de 9
- 1
Innovative Vector Control Consortium (IVCC)
01.11.2024
- 31.10.2028
Neglected tropical diseases and malaria cause severe health and economic challenges in the poorest regions. SDC supports innovative solutions by fostering public-private partnerships to develop and ensure access to safe and effective insecticides. These efforts align with Swiss values of collaboration and innovation, contributing to sustainable health and poverty reduction progress.
Core Contribution Swiss Malaria Group (SMG)
01.01.2024
- 31.12.2027
The Swiss Malaria Group (SMG) is a Swiss-based public, private academic and civil society leadership network that works towards a malaria-free world. SMG member organisations coordinate their efforts to engage technical expertise, opinion-makers and the general public to provide Swiss leadership against malaria, strengthen research and innovation by Swiss actors, and fight malaria in low- and middle-income countries.
Global Malaria Technical & Training Support Package (GlobMal) 2024 - 2027
01.01.2024
- 31.12.2027
With increased cases and death globally (2019, 2020, 2021) and being off track to meet the Sustainable Development Goals 3.3, malaria is a major global health threat, impacting mainly children under 5 in Sub-Saharan Africa. This burden is exacerbated by new challenges such as increasing resistance to malarial drugs or climate change. The project aims to shape effective global and national malaria capacities and elimination strategies, by providing the necessary scientific evidence and strengthening capacities of malaria-affected countries.
Core Contribution to the Global Fund to Fight AIDS, Tuberculosis and Malaria 2023-2025
01.01.2023
- 31.12.2025
The Global Fund collects and channels a big share of international funds to end HIV/AIDS, tuberculosis and malaria, which mostly affect the poorest and most vulnerable people in low- and middle-income countries. Its support to country programmes has saved 44 million lives since 2002. In the coming years, the challenge is to regain lost ground in the fight against the three diseases and to further strengthening health systems to ensure impact, sustainability, and better preparedness and response to pandemics.
Phase 1 Solidarit'Eau Suisse 2022-2027
16.07.2022
- 15.07.2027
Access to safe water and sanitation affordable for all by 2030 according to the Sustainable Development Goal (SDG) 6 is substantially off track. The so-called SDG 6 Acceleration Framework adopted in 2020 by the UN, calls for fast results through increased efforts at all levels and by all relevant actors. Solidarit’Eau Suisse helps in mobilizing support from Swiss municipalities and other water-related public actors to implement Swiss projects in the water sector of the Global South.
MMV - Medicines for Malaria Venture
01.01.2022
- 31.12.2024
Treating malaria requires developing different medicines suitable for people in lower-income countries. The Geneva-based Medicines for Malaria Venture (MMV) drives the discovery, development and implementation of new antimalarial medicines. Working with pharmaceutical, academic and affected country partners, including Swiss companies and research, MMV contributes to equitable access to affordable and quality medicines for vulnerable groups at risk of malaria, in particular children and pregnant women.
Swiss Malaria Group (SMG)
01.01.2020
- 31.12.2023
The Swiss Malaria Group (SMG) gathers all Swiss-based institutions active nationally and internationally in the fight against malaria. The 16 members’ organizations from the public, private, academic and non-for-profit sectors coordinate their efforts in order to engaging Swiss technical expertise, opinion makers and the general public to provide Swiss leadership against malaria at global and national levels, strengthen research and innovation by Swiss actors and fight malaria on the ground in all affected settings.
Towards Elimination of Malaria in Tanzania
01.12.2018
- 30.04.2025
Tanzania deploys innovative approaches for malaria control and elimination since 2000. To sustain and expand gains that have been achieved, the project will capacitate Tanzanian institutions to engage in subnational, intersectoral and cross borders elimination strategies, thus making available best practices to normative bodies such as World Health Organization (WHO). Tanzania’s and Switzerland’s recognized strong expertise, network and influence in malaria elimination will be increased through this programme.
Medicines for Malaria Venture (MMV)
01.01.2017
- 31.12.2021
To contest the increasing problem of drug resistance and to accelerate malaria elimination, new drugs against malaria are needed. The Geneva-based Medicines for Malaria Venture (MMV) drives the discovery, development and implementation of new antimalarial drugs. Working with pharmaceutical, academic and affected country partners, MMV reduces costs and ensures affordable and equitable access to quality medicines by vulnerable groups at risk of malaria, in particular children and pregnant women.
Objet 1 9 de 9
- 1